TME Pharma N.V.
Developing therapies for aggressive cancers by neutralizing the tumor microenvironment.
ALTME | Euronext Growth
Overview
Corporate Details
- ISIN(s):
- NL0015000YE1 (+1 more)
- LEI:
- 724500EPNADXWZ58U595
- Country:
- Germany
- Address:
- Max-Dohrn-Strasse 8-10, 10589 Berlijn
- Website:
- https://www.tmepharma.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
TME Pharma N.V. is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of aggressive cancers. The company specializes in targeting the tumor microenvironment (TME). Its proprietary technology aims to neutralize chemokines within the TME, thereby breaking tumor protection barriers against the immune system and blocking tumor repair mechanisms. This approach is designed to be used in combination with other treatments to weaken tumor defenses and enhance overall therapeutic efficacy. The company's clinical pipeline includes programs for glioblastoma and pancreatic cancer, with its lead candidate, NOX-A12, showing promising results in clinical trials.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-06-18 08:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 255.7 KB | ||
| 2025-06-18 08:00 |
M&A Activity
Informations privilégiées / Autres communiqués
|
French | 287.8 KB | ||
| 2025-05-27 08:00 |
Capital/Financing Update
Inside Information / Other news releases
|
English | 386.1 KB | ||
| 2025-05-27 08:00 |
Capital/Financing Update
Informations privilégiées / Autres communiqués
|
French | 388.7 KB | ||
| 2025-05-26 08:00 |
Pre-Annual General Meeting Information
Informations privilégiées / Autres communiqués
|
French | 261.4 KB | ||
| 2025-05-26 08:00 |
Pre-Annual General Meeting Information
Inside Information / Other news releases
|
English | 222.6 KB | ||
| 2025-05-21 08:00 |
Capital/Financing Update
Informations privilégiées / Autres communiqués
|
French | 329.1 KB | ||
| 2025-05-21 08:00 |
Capital/Financing Update
Inside Information / Other news releases
|
English | 286.1 KB | ||
| 2025-05-05 18:00 |
Director's Dealing
Inside Information / Other news releases
|
English | 243.3 KB | ||
| 2025-05-05 18:00 |
Director's Dealing
Informations privilégiées / Autres communiqués
|
French | 255.1 KB | ||
| 2025-05-05 08:00 |
Board/Management Information
Inside Information / Other news releases
|
English | 281.1 KB | ||
| 2025-05-05 08:00 |
Board/Management Information
Informations privilégiées / Autres communiqués
|
French | 287.8 KB | ||
| 2025-04-25 18:00 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 351.1 KB | ||
| 2025-04-25 18:00 |
Earnings Release
Inside Information / News release on accounts, results
|
English | 275.9 KB | ||
| 2025-04-10 19:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 224.0 KB |
Automate Your Workflow. Get a real-time feed of all TME Pharma N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for TME Pharma N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for TME Pharma N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
%20Co.%2C%20Ltd/other/SLSBioSpecialty_Lab_Solution_Bio_Co._Ltd-logo.jpg){kind=logo}